PO-0752: Isotoxic Intensity Modulated Radiotherapy in stage III NSCLC – A feasibility study. (April 2018) - Haslett, K.; Ashcroft, L.; Bayman, N.; Franks, K.; Groom, N.; Hanna, G.; Harden, S.; Harris, C.; Harrow, S.; Hatton, M.; McCloskey, P.; McDonald, F.; et al.